

Exploring the Impact of Machine Learning and Artificial Intelligence in Drug Development from Discovery to Healthcare

SMi Reports: 3rd Annual AI in Drug Discovery returns to London, March 2022 with a key focus on the opportunities of machine learning and AI in drug development

LONDON, UNITED KINGDOM,
November 12, 2021 /

EINPresswire.com/ -- SMi Group is delighted to announce the [3rd Annual AI in Drug Discovery conference](#), taking place on the 14th and 15th March 2022 in London, UK. The 2022 Conference theme is on exploring the opportunities of machine learning.

Chair for the conference is industry expert Darren Green, Director of Molecular Design, GSK.



SMi's 3rd Annual
AI in Drug Discovery
14 - 15 March 2022
London, UK
#SMiAIDrugDis
www.ai-indrugdiscovery.com

The poster features a dark blue background with a glowing blue DNA double helix structure on the right side. The text is white and orange. The SMi logo is in the top right corner.

New to 2022 is the [AI in Drug Discovery post conference workshops](#) on: "From Drug Discovery to Healthcare, an AI insight" and "Deciphering AI Based Drug Discovery" taking place on 16th March 2022.

Interested parties can register for the conference and workshops at <http://www.ai-indrugdiscovery.com/PR1ein> and take advantage of the early bird offer to save £400 which expires 30th November 2021.

The conference will also bring together [expert speakers which include:](#)

- Andrew Pattison, Digital Health and Innovation Team, World Health Organisation
- Gregory Vladimer, VP Translation Research, Translation Biology, Exscientia
- Kim Branson, SVP Global Head of Artificial Intelligence and Machine Learning, GSK

- Christian Tyrchan, Associate Director Computational Chemistry, AstraZeneca
- Friedrich Rippmann, Computational Chemistry & Biology, Merck
- Mathew Divine, Senior Data Scientist, Boehringer Ingelheim
- Alexander Hillisch, Pharmaceuticals, R&D, Computational Molecular Design, Bayer AG
- Peter Henstock, Machine Learning & AI Technical Lead, Merck

By attending the conference, attendees will have the chance to:

- Discover the main topics of research within industry, with talks on decision making, target selection and closing the loop
- Engage with regulators about the guidance within machine learning and AI in Drug Discovery
- Learn about the new breakthroughs within clinical trials and the treatment of disease
- Explore the latest technologies in deep learning from leaders within the pharmaceutical industry
- Discuss the impact of big data and how it applies to AI drug discovery within Pharma

Attend the SMI's 3rd annual AI in Drug Discovery conference and explore the latest industry updates in the selection of targets using AI, decision making within drug discovery and closing the loop on AI in drug discovery.

Leading presentations from leaders within the field who will be giving their insights into the latest industry advances and answering the big questions within AI in Drug Discovery.

View the agenda and speaker line-up at <http://www.ai-indrugdiscovery.com/PR1ein>

Sponsored by Optibrium

For sponsorship enquiries contact Alia Malick, Director on +44 (0)20 7827 6168 or e-mail amalick@smi-online.co.uk

For media enquiries or a press pass contact Simi Sapal, Head of Marketing on +44 (0) 20 7827 6000 or email ssapal@smi-online.co.uk

SMI's 3rd Annual AI in Drug Discovery 2022

15 – 16 March 2022

London, UK

#SMiAIDrugDis

<http://www.ai-indrugdiscovery.com/PR1ein>

--- ENDS ---

About SMI Group:

Established since 1993, the SMI Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We

create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at <http://www.smi-online.co.uk>

Simi Sapal

SMi Group

+44 20 7827 6000

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/556195382>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2021 IPD Group, Inc. All Right Reserved.